Guangdong Hybribio Biotech Co.,Ltd.

Shenzhen Stock Exchange 300639.SZ

Guangdong Hybribio Biotech Co.,Ltd. EPS (Diluted) for the year ending December 31, 2023: USD 0.04

Guangdong Hybribio Biotech Co.,Ltd. EPS (Diluted) is USD 0.04 for the year ending December 31, 2023, a -90.83% change year over year. EPS (Diluted) reflects the company's earnings per share adjusted for the potential dilution that could occur if all convertible securities were converted to common stock, providing a more conservative profitability measure.

Guangdong Hybribio Biotech Co.,Ltd. EPS (Diluted) for the year ending December 31, 2022 was USD 0.38, a 87.69% change year over year.
Guangdong Hybribio Biotech Co.,Ltd. EPS (Diluted) for the year ending December 31, 2021 was USD 0.20, a 126.35% change year over year.
Guangdong Hybribio Biotech Co.,Ltd. EPS (Diluted) for the year ending December 31, 2020 was USD 0.09, a 151.78% change year over year.
Guangdong Hybribio Biotech Co.,Ltd. EPS (Diluted) for the year ending December 31, 2019 was USD 0.04, a 29.95% change year over year.

Key data

Date	EPS (Diluted)	Shares (Diluted, Weighted)	Shares (Basic, Weighted)	Revenue

Shenzhen Stock Exchange: 300639.SZ

Guangdong Hybribio Biotech Co.,Ltd.

CEO	Ms. Jianyu Wang
IPO Date	April 13, 2017
Location	Hong Kong
Headquarters	50 Bonham Strand
Employees	2,669
Sector	Healthcare
Industries Biotechnology Cleaning Supplies Medical Instruments Personal Care Pharmaceuticals

Description

Guangdong Hybribio Biotech Co.,Ltd. engages in the research and development, manufacture, and sale of nucleic acid molecular diagnostic products for hospitals and medical institutes. It provides in-vitro diagnostic kits for human papilloma virus, sexually transmitted diseases (STD), thalassemia, and prenatal and postnatal. The company also offers STD real time PCR kits; hepatitis B virus real-time PCR kits and thalassemia genoarray diagnostic kits; hearing loss susceptibility genoarray diagnostic kits; COVID-19 real-time PCR kits; and devices/instruments, including automated nucleic acid extraction, automatic medical PCR analysis, flow-through hybridization, auto DNA extraction, and fluorescent quantitative detection systems, as well as after-sales technical service support. Its products are used in the fields of national screening, clinical, and research purposes. The company operates in the Asia Pacific, the South East Asia, the Middle East, Europe, Africa, and South America. Guangdong Hybribio Biotech Co.,Ltd. was founded in 2003 and is based in Sheung Wan, Hong Kong.

Key trends

Past 5 years